Homburger on Biopas sale to Swixx Biopharma
Homburger advised Biopas on its sale to Swixx Biopharma, a swiss-based global commercial platform focusing on guaranteeing access to innovative medicines worldwide. The founders of Biopas will become shareholders of Swixx Biopharma. The transaction is expected to close in June or July 2024, subject to regulatory approvals and customary conditions.
Biopas’ acquisition forms part of Swixx Biopharma’s announced strategic expansion into Latin America.
Homburger’s team
Homburger advised Biopas and its founders, operating with a team comprising Andreas Müller (pictured), Anna Peter, Hans Glent Abildgaard and Harun Cetin (all corporate / M&A), Stefan Bindschedler (financing and investment products) as well as Reto Heuberger and Philippe Weber (both tax).
On Biopas
Founded in 2002 and head-quartered in Bogota, Colombia, Biopas is a pharmaceutical company in Latin America. It specializes in the in-licensing, marketing, and sale of cutting-edge specialty pharmaceutical products, with annual sales of approx. USD 220 millions.
